Neuland Laboratories announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2025. The company reported a total income of ₹816.68 million and profit after tax of ₹110.75 million for the half-year. The standalone revenue from operations stood at ₹807.03 million.
Financial Performance
For the half-year ended September 30, 2025, Neuland Laboratories reported the following consolidated results:
- Total Income: ₹816.68 million
- Profit before tax: ₹147.01 million
- Profit after tax: ₹110.75 million
The standalone results include:
- Revenue from operations: ₹807.03 million
Segmental Performance
The company’s operations predominantly involve the manufacture and sale of active pharmaceutical ingredients and allied services, constituting a single reportable segment.
Assets and Liabilities
As of September 30, 2025, the company’s consolidated assets and liabilities include:
- Total Equity: ₹1,620.16 million
- Total Assets: ₹2,534.03 million
Key balance sheet items include inventories valued at ₹547.90 million and trade receivables at ₹440.92 million.
Additional Highlights
- Earnings per share for the period stood at ₹86.32.
Source: BSE
